Besides preventing diabetes-induced neurodegeneration, topical administration of semaglutide inhibits the disruption of the blood-retinal barrier and the subsequent vascular leakage, thus confirming the dual effect of GLP-1R agonists. The gene discussed is GLP1R; the disease is diabetes mellitus.